Target-directed development and preclinical characterization of the proposed biosimilar rituximab GP2013

Biosimilar development involves a target-directed iterative process to ensure a similar product to the originator. Here we report the preclinical development of the proposed biosimilar rituximab (GP2013). Post-translational modifications and bioactivities of GP2013 versus originator rituximab were e...

Descripción completa

Detalles Bibliográficos
Autores principales: da Silva, Antonio, Kronthaler, Ulrich, Koppenburg, Vera, Fink, Martin, Meyer, Ines, Papandrikopoulou, Anastassia, Hofmann, Matthias, Stangler, Thomas, Visser, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Informa Healthcare 2014
Materias:
Original Article: Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4133973/
https://www.ncbi.nlm.nih.gov/pubmed/24024472
http://dx.doi.org/10.3109/10428194.2013.843090

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4133973/
https://www.ncbi.nlm.nih.gov/pubmed/24024472
http://dx.doi.org/10.3109/10428194.2013.843090

Ejemplares similares